ACT Brief: Reframing Site Initiation Readiness, Operational Execution as Competitive Advantage, and a Historic Motion Sickness Approval

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated readiness, examine how AI and decentralized infrastructure are reshaping clinical operations strategy, and review FDA’s approval of the first new pharmacologic motion sickness treatment in more than four decades.